Synthesis of Lenacapavir Sodium: Active Pharmaceutical Ingredient Process Development and Scale-up

Lenacapavir sodium (GS-6207-02) is a first-in-class HIV capsid inhibitor. Process development of the four-step final assembly of lenacapavir sodium from four synthetic intermediates is described here. A bis-bromopyridine core is sequentially subjected to an alkynylation, an amide coupling with a chi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Organic process research & development 2024-08, Vol.28 (8), p.3382-3395
Hauptverfasser: Wagner, Anna M., Bonderoff, Sara A., Chang, Stanley, Deignan, Jeffrey, Esanu, Michelle M., Van Huynh, Huy, Niu, Tianmin, Ngo, Vinh, O’Keefe, B. Michael, Phoenix, Jenny, Rainey, Trevor J., Roberts, Benjamin J., Shen, Jinyu, Stewart, Craig, Vandehey, Amanda L., Wolckenhauer, Scott A., Wong, Chloe Y., Yarmuch, Brian H.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Lenacapavir sodium (GS-6207-02) is a first-in-class HIV capsid inhibitor. Process development of the four-step final assembly of lenacapavir sodium from four synthetic intermediates is described here. A bis-bromopyridine core is sequentially subjected to an alkynylation, an amide coupling with a chiral pyrazole carboxylic acid, and a Suzuki cross-coupling with an indazole boronic ester. The final step is a telescoped bis-methanesulfonylation and hydrolysis to yield the API. This report highlights experimental work on the final assembly sequence to establish robust processing conditions, minimize process mass intensity, control impurity formation, understand impurity purge, and enable large-scale manufacturing of lenacapavir sodium.
ISSN:1083-6160
1520-586X
DOI:10.1021/acs.oprd.4c00242